Clinical Opioid Withdrawal Scale

US WorldMeds Announces Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic

Retrieved on: 
Thursday, July 9, 2020

LOUISVILLE, Ky., July 9, 2020 /PRNewswire/ --USWM LLC dba US WorldMeds (USWM), a Kentucky-based company, has today announced their partnership with the Federal Emergency Management Agency (FEMA) and Healthcare Ready in bringing urgently needed opioid withdrawal medication to communities in need during the current coronavirus pandemic.

Key Points: 
  • LOUISVILLE, Ky., July 9, 2020 /PRNewswire/ --USWM LLC dba US WorldMeds (USWM), a Kentucky-based company, has today announced their partnership with the Federal Emergency Management Agency (FEMA) and Healthcare Ready in bringing urgently needed opioid withdrawal medication to communities in need during the current coronavirus pandemic.
  • While not a treatment for OUD, LUCEMYRA is the only non-opioid medication approved by the FDA for treatment of opioid withdrawal symptoms*.
  • *LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for Opioid Use Disorder.
  • COVID has highlighted how left behind our patients have been in the pandemic with substance use disorder rates rising.

BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms

Retrieved on: 
Wednesday, February 5, 2020

There is an urgent need for better treatment options to help manage the debilitating withdrawal symptoms and aid this underserved population from continued opioid abuse.

Key Points: 
  • There is an urgent need for better treatment options to help manage the debilitating withdrawal symptoms and aid this underserved population from continued opioid abuse.
  • BXCL501, our investigational non-opioid therapy, may offer key advantages to treating symptoms due to its intrinsic potency and favorable delivery method.
  • BXCL501 selectively activates alpha-2a adrenergic receptors, which decreases excessive neuronal firing, alleviating the physiological symptoms of opioid withdrawal.
  • The study will assess opioid withdrawal symptoms using both the Clinical Opiate Withdrawal Scale and Short Opiate Withdrawal Scale of Gossop over a 10-day period.